Clinical trial · Observational
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer：a Prospective Single-center Research Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The early symptoms of pancreatic cancer are not obvious, and the early diagnosis rate is low. For most patients with pancreatic cancer,palliative chemotherapy is the only choice .At present, The guidance of NCCN guidelines on the selection of chemotherapy regimens for patients with advanced pancreatic cancer is only based on the physical condition(the ECOG score), which is one of the important reasons for the poor efficacy of chemotherapy in patients with advanced pancreatic cancer.Therefore, it is urgent to group pancreatic cancer patients according to tumor molecular typing and heterogeneity of response to chemotherapy drugs accurately,so as to guide the personalized treatment of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma, PDAC | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Accuracy of using the model to predict the therapeutic effect of drugs
- timeFrame
- 1.5 years
- description
- The difference of progression free survival (PFS)
Secondary outcomes (2)
- measure
- Efficacy evaluation of solid tumor
- timeFrame
- 1.5 years
- description
- disease control rate (DCR)
- measure
- the quality of participants'life
- timeFrame
- 1.5 years
- description
- According to the European Organization for research and treatment of cancer (EORTC) quality of life core scale EORTC QLQ-C30 (V3.0 Chinese version)，evaluating the quality of life (QOL)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \> 18 years old, male or female; 2. Locally advanced or metastatic pancreatic ductal adenocarcinoma confirmed by histopathology / cytology of the primary and / or metastatic lesions and not suitable for surgical resection, and don't receive chemotherapy; 3. According to the evaluation criteria of solid tumor efficacy(RECIST 1.1), there should be at least one measurable lesion (non nodular lesion with the longest diameter of 210 mm, or nodular lesion with the shortest diameter of more than 15 mm); 4. Patients voluntarily participate in this study, sign informed consent, have good compliance, and cooperate with follow-up. Exclusion Criteria: If any of the following criteria is met, the patient should be excluded: 1. Pancreatic ductal adenocarcinoma is diagnosed without histopathology / cytology; 2. The target lesion has received local non-drug therapy (including radiotherapy, physical and / or chemical ablation, etc.), and there is no imaging progression; 3. If the central nervous system metastasis is known, MRI should be performed to exclude it.
References
Publications (1)
- DERIVEDZhang Y, Du Y, Wang J, Wang D, Li J, Zhang J, Zhao Y, Sun S, Sun H, Qi J, Bao R, Shao C, Zhang M, He X, Zhang L, Zhou C, Wang D, Su B, Zou D, Ye Y. Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer. Gastroenterology. 2026 Apr;170(4):769-786. doi: 10.1053/j.gastro.2025.09.043. Epub 2026 Feb 17. PMID 41701125